Introduction

In recent years, the development of neuroimaging techniques such as high-resolution magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), positron emission tomography (PET), or single photon emission tomography (SPECT) has promoted the identification of structural and functional characteristics underlying mental disorders to a great extent. In anxiety disorders, recent neuroimaging techniques have contributed greatly to diagnosis and treatment, and helped to shed light on the neurobiological basis of anxiety in general.¹ The number of neuroimaging studies conducted on anxiety disorders has risen constantly since the 1980s.² According to DSM-IV, anxiety disorders include diagnoses of panic disorder, agoraphobia, post-traumatic stress disorder (PTSD), social anxiety disorder (social phobia), specific phobias, generalized anxiety disorder (GAD), and obsessive-compulsive disorder (OCD).³ The common feature of the different anxiety disorders is excessive, irrational fear and avoidance of anxiety triggers.³ Numerous studies have been conducted so far to determine structural and functional neural pathways of anxiety disorders and anxiety in general. Furthermore, there have been attempts to disentangle the neurobiological basis of anxiety in general.¹ The number of neuroimaging studies conducted on anxiety disorders has risen constantly since the 1980s.²

Keywords: anxiety disorder; neuroimaging; functional magnetic resonance imaging; amygdala; treatment

© 2011 LLS SAS

Dialogues Clin Neurosci. 2011;13:453-461.

Over the last few years, neuroimaging techniques have contributed greatly to the identification of the structural and functional neuroanatomy of anxiety disorders. The amygdala seems to be a crucial structure for fear and anxiety, and has consistently been found to be activated in anxiety-provoking situations. Apart from the amygdala, the insula and anterior cingulate cortex seem to be critical, and all three have been referred to as the “fear network.” In the present article, we review the main findings from three major lines of research. First, we examine human models of anxiety disorders, including fear conditioning studies and investigations of experimentally induced panic attacks. Then we turn to research in patients with anxiety disorders and take a close look at post-traumatic stress disorder and obsessive-compulsive disorder. Finally, we review neuroimaging studies investigating neural correlates of successful treatment of anxiety, focusing on exposure-based therapy and several pharmacological treatment options, as well as combinations of both.

Author affiliations: University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Psychiatry Neuroimaging Branch, Hamburg, Germany

Address for correspondence: Prof Dr Christoph Mulert, Martinistrasse 52, 20246 Hamburg, Germany (e-mail: c.mulert@uke.de)
logical characteristics specific to each disorder. However, the number of neuroimaging studies conducted on each anxiety disorder varies greatly. Most of the imaging studies on anxiety disorders published within the last decade focused on PTSD or OCD; less research has been conducted on agoraphobia and generalized anxiety disorder, for example. In addition to imaging studies in patients with anxiety disorders, a large body of research has been conducted on anxiety in healthy subjects. For example, fear conditioning studies or experimentally induced panic attacks in healthy individuals resembled the elevated fear response seen in anxiety disorder patients quite well.

The present review attempts to create a global overview of the current findings of structural MRI, fMRI, and PET studies in the field of anxiety disorders. In the following, we first discuss research on models of anxiety in healthy subjects, then turn to clinical studies in anxiety patients, and conclude with an outlook on the possibility of visualizing the effects of pharmacological and psychotherapeutic treatment of anxiety disorders using neuroimaging techniques.

**Modeling anxiety in healthy individuals**

Classical fear conditioning was one of the first experimental paradigms employed to study the functional neuroanatomy of anxiety in healthy humans. In fear conditioning studies, a previously neutral stimulus is repeatedly paired with an aversive stimulus which by itself elicits an autonomic fear response. After several paired presentations, the previously neutral stimulus becomes “conditioned” and elicits the autonomic fear response alone. In a well-known study by Büchel et al, neutral faces were conditioned with an unpleasantly loud tone. After conditioning, presentation of the conditioned stimulus evoked brain activity in the anterior cingulate cortex, the anterior insula, and the amygdala (Figure 1). Interestingly, amygdala activation decreased over time, indicating a rapid habituation of this structure. The finding that the amygdala, the insula, and the anterior cingulate cortex are part of an aversive conditioning network has been replicated many times within the last years. Furthermore, the results of the early fear conditioning studies already pointed to the “fear network” commonly found to be activated in imaging studies in anxiety disorders during symptom provocation. Not only the acquisition of anxiety but also mechanisms of extinction can be modeled by fear conditioning paradigms. During extinction of a conditioned fear response, the previously neutral stimulus is repeatedly presented without the aversive stimulus and the conditioned fear response is gradually eliminated. Neuroimaging of fear extinction revealed that most of the regions involved in fear conditioning are active during the extinction process as well. Again, and most consistently, activation in the fear network, including the amygdala, the insula, and the anterior cingulate cortex, was found during extinction. Moreover, there is evidence for activation in prefrontal regions during fear extinction.

![Figure 1](image-url)
extinction that might reflect a regulating effect of prefrontal structures on the amygdalar fear reaction, in that the expression of fear as a reaction to a fearful stimulus is inhibited. Extinction of fear is a process which is important for the treatment of anxiety disorders, particularly for exposure-based psychotherapeutic approaches, and changes in functional neuroanatomy seen during extinction resemble the functional changes after successful treatment of anxiety disorders quite well (see below).

Another experimental model of human anxiety is the induction of panic attacks with panicogenic substances, like the synthetic neuropeptide cholecystokinin tetrapeptide (CCK-4). A panic attack is a period of intense fear and anxiety along with numerous physical symptoms, eg, sweating, trembling, chest pain, and discomfort; the recurrence of unexpected, sudden panic attacks characterizes panic disorder. CCK-4-induced panic attacks closely resemble spontaneously occurring panic attacks experienced by panic disorder patients, and CCK-4 is assumed to be an ideal and valid agent for the experimental induction of panic attacks. CCK-4-induced panic can therefore serve as a useful model to study the pathophysiology and neurobiological basis of panic disorder. In studies investigating the functional neuroanatomy of CCK-4-induced panic, CCK-4 and placebo injections are delivered during PET or fMRI scanning and brain activity is recorded meanwhile. Contrast imaging during CCK-4, placebo, and periods of anticipatory anxiety with baseline activity then reveals what brain regions might be involved in the generation of panic attacks. Eser et al found large responses to CCK-4 injection in the ventral anterior cingulate cortex (ACC), middle and superior frontal gyrus, precuneus, middle and superior temporal gyrus, occipital lobe, sublobar areas, cerebellum, and brainstem. Moreover, amygdala activation during CCK-4 was significantly higher than during placebo, especially in individuals that experienced more severe symptoms of fear. This finding indicates that the experience of CCK-4-induced fear might be related to the extent of amygdala activation and emphasizes its role in fear and anxiety.

Furthermore, CCK-4 models of panic disorder not only serve to uncover the functional neuroanatomy of panic attacks but can also point to putative genomic risk factors for anxiety, the influence of personality factors on proneness to anxiety, or the effect of drugs on brain activity and symptoms of fear. To summarize, human models of anxiety in healthy individuals can help to reveal neural processes underlying the development of anxiety disorders, the expression of fear during symptom provocation, and the extinction of fear during treatment of anxiety. Brain structures found to be involved in fear conditioning in healthy humans (ie, the fear network) have been shown to underlie clinically relevant anxiety disorders as well.

**Neuroimaging of anxiety disorders**

The majority of functional neuroimaging studies investigating anxiety disorders employed a symptom provocation paradigm. They contrasted a negative emotional condition (eg, pictures of feared objects or situations) with a neutral or positive condition to elicit anxiety-specific brain activity, and then compared activity in anxiety disorder patients with healthy controls. For example, individuals with a social anxiety disorder were confronted with pictures of angry faces, PTSD patients were exposed to pictures of trauma-related scenes and sounds, and spider phobic individuals saw pictures of spiders. One of the most consistent findings of these studies is a hyperactivity of the amygdala during symptom provocation that is related to the experienced symptoms of fear. The amygdala is a group of nuclei located in the medial temporal lobe. It is involved in several fear and emotion related processes like fear conditioning, the regulation of stress effects on memory, reward learning, and the processing of emotionally and socially relevant information. Recently, more general approaches assume that the amygdala codes salience or relevance or value and is therefore a crucial structure for a larger number of processes. Apart from the amygdala, further brain regions like the anterior cingulate cortex and the insula were shown to be involved in the development and maintenance of anxiety disorders as well. They have previously been referred to as “the fear network.” The insula is a central structure for emotion processing, for subjective feelings and interoceptive awareness, and the anterior cingulate cortex plays an important role in approach and avoidance and fear learning. In general, all of the fear network regions seem to be involved in “the processing of emotions as they relate to the self” and thus play a role in fear and anxiety as well. Imaging studies in almost all of the anxiety disorders have consistently demonstrated enhanced
activation in the fear network during symptom provocation.
The most extensive research in the field of neuroimaging in anxiety disorders has been conducted on PTSD. PTSD is an anxiety disorder that is caused by the experience of an extremely stressful event that involved actual or threatened death, serious injury, or a threat to the physical integrity of self or others. PTSD is characterized by re-experiencing this traumatic event, avoidance of the stimuli associated with the event, and a persistently increased arousal. Functional neuroimaging studies have recurrently demonstrated amygdalar hyperactivity in PTSD (Figure 2) and hypoactivity in the medial prefrontal cortex and anterior cingulate cortex. There is evidence for reduced hippocampal activity as well. In current models of PTSD, amygdalar hyperactivity reflects the persistently elevated fear response, and hypoactivity in frontal regions suggests a reduced potential for top-down regulation of fear and fear extinction. The hippocampus provides information about the context of a situation and the attenuated hippocampal response might be attributable to difficulties in identifying safe contexts. In addition to the functional abnormalities described above, structural changes in several brain regions, including the hippocampus, amygdala, and medial prefrontal cortex, have been demonstrated in PTSD patients as well. Interestingly, not all people exposed to a traumatic event develop PTSD as a consequence. Hence, this raises the question of whether the structural and functional abnormalities predispose to or follow the development of PTSD, and there seem to be mixed results in the literature. However, studies conducted so far point to a two-way relationship. They indicate that some of the observed abnormalities, like reduced hippocampal volume, can be a predisposing factor for the development of PTSD on the one hand, but also be a consequence of the disorder and show a further decrease over time.

Another anxiety disorder that has attracted much attention in neuroimaging research within the last few years is OCD. OCD is characterized by the presence of recurrent and persistently disturbing thoughts and images (obsessions), mostly followed by repetitive behaviors (compulsions) to reduce anxiety. Compulsions typically include washing, ordering, or checking. According to a widely accepted model, the cortico-striatal model of OCD, the primary pathology of OCD lies within the striatum, specifically the caudate nucleus. A striatal dysfunction leads via direct and indirect pathways to inefficient thalamic gating, which in turn results in hyperactivity within the orbitofrontal and anterior cingulate cortex. Orbitofrontal hyperactivity is associated with the occurrence of intrusive thoughts, while hyperactivity within the anterior cingulate cortex is considered to be reflected in unspecific anxiety arising from these thoughts. Within this model, compulsions are assumed to be performed to compensatory activate the striatum, achieve thalamic gating, and thus neutralize intrusive thoughts and anxiety. The cortico-striatal model is consistent with neuroimaging studies demonstrating abnormal functional connectivity and increased brain activity in orbitofrontal and ACC regions during rest and during presentation of OCD-related stimuli. Consistent with findings from functional imaging studies, structural abnormalities in OCD patients have been found in key regions of the frontal-striatal circuit, like the orbitofrontal cortex, the anterior cingulate cortex, the basal ganglia, and the thalamus. Although OCD is considered an anxiety disorder, there is limited evidence for a prominent role of the amygdala in the pathophysiology of this disorder, and anxiety symptoms have rather been linked to hyperactivity in the anterior cingulate cortex. Simon et al addressed this issue and investigated brain activation during individually tailored symptom provocation. As expected, they demonstrated increased activation of fronto-striatal areas in OCD-patients compared with healthy controls in response to OCD-related stimuli, contrasted with neutral and generally aversive but symptom-unrelated stimuli. However, amygdala hyperactivation in patients was found during OCD-related symptom provocation and during presentation of unrelated aversive stimuli. Thus, the authors argue that amygdala hyperactivation in OCD patients might reflect general emotional hyperarousal rather than OCD-related anxiety. In summary, studies in patients with anxiety disorders rather consistently demonstrated activity of the “fear network” during symptom provocation. Symptoms of anxiety are considered to be due to a pathologically hyperactivated amygdala and insufficient top-down regulation by frontal brain regions. However, at least in OCD, there seems to a network of regions distinctly activated in this disorder. Further research will probably identify more specific regions involved in the development and maintenance of each anxiety disorder.
Imaging neural correlates of treatment in anxiety disorders

Among psychotherapeutic interventions, cognitive-behavioral therapy (CBT), particularly exposure therapy, has been shown to be highly effective in the treatment of anxiety disorders. During exposure therapy, patients are systematically and repeatedly exposed to the anxiety-provoking stimulus or situation until their fear subsides. The exact neural mechanisms of this potent intervention remain to be determined. However, exposure therapy appears to be quite similar to the process of fear extinction and thus might recruit similar brain structures as well. In line with this assumption, several studies have been conducted within the last few years that demonstrated changes in brain structure and function after successful anxiety treatment with exposure therapy. Goossens et al. demonstrated altered patterns of neural functioning after successful treatment of specific phobia. People suffering from specific phobia show an elevated fear response cued by the presence or anticipation of a specific object or situation. Common phobic stimuli are animals, heights, flying, receiving an injection, and seeing blood. On the neuronal level, confrontation with or anticipation of the phobic stimulus usually produces an elevated response in the fear network, in patients with specific phobia. In a sample of spider phobic individuals, amygdala activity decreased after successful exposure therapy, compared with pretreatment activity (Figure 3). Furthermore, a normalization of insular and anterior cingulate cortex activity was found. In OCD, changes in patterns of brain activity were seen after CBT comprising exposure and response prevention strategies. Dickie et al. investigated the neural correlates of recovery from PTSD and found activity in the hippocampus and the subgenual anterior cingulate cortex to correlate with improvement in PTSD symptoms. Activity in the amygdala and ventral-medial prefrontal cortex was associated with current symptom severity.

A novel line of research investigated the application of D-cycloserine, a partial N-methyl-D-aspartate (NMDA) receptor agonist, in combination with exposure-based therapy in the treatment of anxiety disorders. D-cycloserine facilitates the effectiveness of exposure therapy, in that it speeds up fear extinction processes. Neuroimaging in spider phobic patients suggests that during symptom provocation D-cycloserine enhances activation in regions involved in cognitive control and interoceptive integration, like the prefrontal cortex, the

Figure 2. Activation in the right amygdala is enhanced in post-traumatic stress disorder (PTSD) patients compared with trauma-exposed non-PTSD participants (TENP) during the presentation of emotionally negative pictures. Fix, fixation baseline; Neg, negative; Neut, neutral.
Reprinted from ref 43: Brohawn KH, Offringa R, Pflaff DL, Hughes KC, Shin LM. The neural correlates of emotional memory in posttraumatic stress disorder. Biol Psychiatry. 2010;68:1023-1030. Copyright © Elsevier, 2010
anterior cingulate cortex, and the insula. On the behavioral level, this neural modulation might become evident in enhanced extinction of fear.

In addition to exposure-based therapies, there is also evidence for neural changes associated with other psychotherapeutic concepts. For example, behavioral changes in patients with social anxiety disorder after mindfulness-based stress reduction (MBSR) therapy seem to be reflected by distinct patterns of neural activity.

With regard to psychotherapy research, neuroimaging techniques offer the opportunity to monitor structural and functional neuronal changes as a result of psychotherapy that occur along with changes in patients’ perception and behavior and might help to further refine and optimize psychotherapeutic strategies.

Psychopharmacological first-line treatments of anxiety disorders include antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Positive effects of antidepressant medication can be demonstrated using neuroimaging techniques, too. Citalopram, for example, attenuated amygdala response to aversive faces and reduced activity in prefrontal regions, the striatum, the insula, and paralimbic regions during listening to worry sentences in GAD. Thus, SSRI treatment in anxiety disorders seems to alter abnormal neural processes that were found to be key characteristics of fear and anxiety. The anticonvulsant drug pregabalin has an anxiolytic potential, too, and is approved for the use in GAD. In a recent study in healthy individuals, pregabalin attenuated amygdalar and insular activity during anticipation of and during emotional processing.

The neuropeptide oxytocin has stress-reducing and attachment enhancing effects and facilitates social encounters. Thus, it might also have positive effects on emotion regulation in patients suffering from abnormally elevated fear of social situations. In patients with social anxiety disorder, oxytocin attenuated the heightened amygdala activation in response to fearful faces. Hence, it appears to modulate the exaggerated amygdala activity during confrontation with social stimuli in pathological social anxiety. These lines of research suggest that neuroimaging techniques could potentially identify common neural pathways of anxiety treatment, and therefore help us to understand how new pharmacological treatment options for anxiety disorders might work.

Furthermore, there is evidence that pretreatment patterns of functional neuronal activity might predict whether a patient responds to a particular intervention or not. Structural neuroanatomical characteristics were shown to predict response to psychotherapy as well. Bryant et al demonstrated in PTSD patients that a smaller volume of the rostral anterior cingulate cortex predicted nonresponse to CBT. The authors assume that exposure-based CBT is, similarly to the extinction of conditioned fear, a process that requires anterior cingulate cortical structures. Thus, larger volumes of the anterior cingulate cortex would lead to better control over fear responses during exposure therapy and enhanced extinction, and consequently result in better responding to CBT. Therefore, pretreatment characteristics in structural and functional neuroanatomy might become important predictors for the kind of treatment that suits best for a particular patient.

In summary, in the future, neuroimaging techniques might enable therapists and researchers to continuously monitor treatment success. Furthermore, structural and functional neuroimaging studies seem to be a promising tool to reveal the neural mechanisms underlying anxiety disorders and thus may lead to the development of more effective therapeutic options. They might also help to specifically assign patients to treatments that promise to be most effective for a certain individual.

Conclusion

In conclusion, in the present article we have provided an overview of the results of current neuroimaging studies in fear and anxiety. Studies in human models of anxiety, as well as investigations in anxiety disorder patients consistently implicated the crucial role of the “fear network,” comprising the amygdala, insula, and anterior cingulate cortex.
cortex, for the development and maintenance of anxiety disorders. Effective psychotherapeutic and pharmaco-
logical treatments of anxiety seem to specifically alter patterns of brain activation in these structures.

**REFERENCES**

1. Paulus MP. The role of neuroimaging for the diagnosis and treatment of anxiety disorders. *Depress Anxiety*. 2008;25:348-356.
2. Damsa C, Kosel M, Moussally J. Current status of brain imaging in anxiety disorders. *Curr Opin Psychiatry*. 2009;22:96-110.
3. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
4. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. *Am J Psychiatry*. 2007;164:1476-1488.
5. Buchel C, Morris J, Dolan RJ, Friston KJ. Brain systems mediating aversive conditioning: an event-related fMRI study. *Neuron*. 1998;20:947-957.
6. Grillon C. Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. *Biol Psychiatry*. 2002;52:958-975.

---

**Neuroímagenes en los trastornos ansiosos**

**Neuro-imagerie dans les troubles anxieux**

**Durante los últimos años las técnicas de neuroimágenes han contribuido de manera importante a la identificación de la neuroanatomía estructural y funcional de los trastornos ansiosos. La amígdala parece ser una estructura crucial para el miedo y la ansiedad, y constantemente se ha encontrado activada en situaciones que provocan ansiedad. Además de la amígdala, la ínsula y la corteza cingulada anterior también parecen ser muy importantes y las tres se han denominado “el circuito del miedo”. En este artículo se revisan los principales hallazgos de tres importantes líneas de investigación. Primero se examinan modelos humanos de los trastornos ansiosos, incluyendo estudios de miedo condicionado e investigaciones de ataques de pánico inducidos experimentalmente. Luego se aborda la investigación en pacientes con trastornos ansiosos con especial énfasis en el trastorno por estrés postraumático y el trastorno obsesivo-compulsivo. Finalmente se revisan los estudios de neuroimágenes que investigan los correlatos neurales de tratamientos ansiolíticos exitosos, enfocándose en terapias basadas en la exposición y en algunas alternativas psicofarmacológicas, como también en combinaciones de ambas.**

---

**Ces dernières années, les techniques de neuro-imagerie ont largement contribué à l’identification de la neuroanatomie structurale et fonctionnelle des troubles anxieux. Les amygdales, structures capitales pour la peur et l’anxiété, sont régulièrement activées dans des situations pourvoyeuses d’anxiété. À côté des amygdales, l’insula et le cortex cingulaire antérieur semblent d’une importance cruciale, ces trois structures ayant été qualifiées de « réseau de la peur ». Dans cet article, nous passons en revue les principaux résultats de trois axes majeurs de recherche. Tout d’abord, nous examinons des modèles humains de troubles anxieux, à l’aide d’études sur le conditionnement de la peur et d’ennuïes sur les attaques de panique induites expérimentalement. Puis nous nous consacrons à la recherche chez les patients atteints de troubles anxieux et nous examinons de près l’état de stress post-traumatique et les troubles obsessionnels compulsifs. Enfin, nous analysons des études de neuro-imagerie sur les corrélations neurales du traitement efficace de l’anxiété, en nous concentrant sur un traitement basé sur l’exposition (au stimulus anxigene) et sur plusieurs traitements pharmacologiques, comme aussi sur l’association des deux.**

---

**REFERENCES**

7. Klucken T, Kagerer S, Schweckendiek J, Tabbert K, Vaitl D, Stark R. Neural, electrodermal and behavioral response patterns in contingency aware and unaware subjects during a picture-picture conditioning paradigm. *Neuroscience*. 2009;158:721-731.
8. Sehlmeyer C, Schoning S, Zwitserlood P, et al. Human fear conditioning and extinction in neuroimaging: a systematic review. *PLoS One*. 2009;4:e5865.
9. Eser D, Leicht G, Lutz J, et al. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. *Hum Brain Mapp*. 2009;30:511-522.
10. Buchel C, Dolan RJ. Classical fear conditioning in functional neuroimaging. *Curr Opin Neurobiol*. 2000;10:219-223.
11. Phelps EA, Delgado MR, Nearing KJ, LeDoux JE. Extinction learning in humans: role of the amygdala and vmPFC. *Neuron*. 2004;43:897-905.
12. Gottfried JA, Dolan RJ. Human orbitofrontal cortex mediates extinction learning while accessing conditioned representations of value. *Nat Neurosci*. 2004;7:1144-1152.
13. Yaguez L, Coen S, Gregory LJ, et al. Brain response to visceral aversive conditioning: a functional magnetic resonance imaging study. Gastroenterology. 2005;128:1819-1829.
14. Quirk GJ, Lukthit E, Pelletier JG, Pare D. Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. J Neurosci. 2003;23:8809-8807.
15. Sotres-Bayon F, Cahn CK, LeDoux JE. Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biol Psychiatry. 2008;60:329-336.
16. Bradwejn J, Koszycki D, Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry. 1990;35:83-85.
17. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991;48:603-610.
18. Bradwejn J, Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl. 2001;234:19-27.
19. Eser D, Schule C, Bashai T, et al. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology (Berl). 2007;192:479-487.
20. Schule C, Eser D, Mathis A, et al. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage. 2006;31:1197-1208.
21. Javannard M, Shili J, Kennedy SH, Vaccarano F, Houle S, Bradwejn J. Neuronanatomical correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry. 1999;45:872-882.
22. Eser D, Uhr M, Leicht G, et al. Glyoxalase-I mRNA expression and CCK-4 induced panic attacks. J Psychiatr Res. 2011;45:60-63.
23. Eser D, Wenninger S, Bashai T, Schule C, Rupprecht R. Impact of state and trait anxiety on the panic response to CCK-4. J Neural Transm. 2008;115:917-920.
24. Toru I, Alouga A, Vohma U, et al. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Psychiatry Res. 2010;178:342-347.
25. Schunk T, Mathis A, Erb G, et al. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. J Psychopharmacol. 2011;25:52-59.
26. Zwanger P, Eser D, Notthdurfer C, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Psychiapharmacology. 2009;204:266-269.
27. Bremner JD, Stath L, Kolupeck D, Southwick SM, Soufer R, Charney DS. Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study. Biol Psychiatry. 1999;45:806-816.
28. Schweckendiek J, Kluken T, Merz C, et al. Weaving the (neuronal) web: fear learning in spider phobia. Neuroimage. 2011;54:681-688.
29. Bremner JD. Brain imaging in anxiety disorders. Exp Rev Neurother. 2004;4:275-284.
30. Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci. 2003;985:389-410.
31. Kent JM, Rauch SL. Neurocircuity of anxiety disorders. Curr Psychiatry Rep. 2003;5:266-273.
32. Rozendaal B, McEvon BS, Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci. 2009;10:423-433.
33. Morrison SE, Salzman CD. Re-valuing the amygdala. Curr Opin Neurobiol. 2010;20:221-230.
34. Sabatinielli D, Fortune LE, Li Q, et al. Emotional perception: meta-analyses of face and natural scene processing. Neuroimage. 2011;54:2524-2533.
35. Adolphs R. What does the amygdala contribute to social cognition? Ann N Y Acad Sci. 2010;1191:42-61.
36. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage. 2003;20:1331-348.
37. Craig AD. How do you feel? Interception: the sense of the physiological condition of the body. Nat Rev Neurosci. 2002;3:655-666.
38. Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ. Neural systems supporting interpersonal awareness. Nat Neurosci. 2004;7:189-195.
39. Freeman JH, Jr, Cuppennell C, Flannery K, Gabriel M. Limbic thalamic, cingulate cortical and hippocampal neuronal correlates of discriminative approach learning in rabbits. Behav Brain Res. 1996;80:123-136.
40. Buchanan SL, Powell DA. Cingulate cortex: its role in Pavlovian conditioning. J Comp Physiol Psychol. 1982;96:755-774.
41. Shin LM, Orr SP, Carson MA, et al. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry. 2004;61:168-176.
42. Bermetten E, Schmali C, Southwick SM, Bremner JD. Positron tomographic emission study of olfactory induced emotional recall in veterans with and without combat-related posttraumatic stress disorder. Psychopharmacol Bull. 2007;40:8-30.
43. Brohaven KH, Offringa R, Pfaff DL, Hughes KC, Shin LM. The neural correlates of emotional memory in posttraumatic stress disorder. Biol Psychiatry. 2010;68:1023-1030.
44. Shin LM, Rauch SL, Pitman RK. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci. 2006;1071:67-79.
45. Hayes JP, Labar KS, McCarthy G, et al. Reduced hippocampal and amygdala activity predicts memory distortions for trauma reminders in combat-related PTSD. J Psychiatr Res. 2011;45:660-669.
46. Deckerbach T, Dougherty DD, Rauch SL. Functional imaging of mood and anxiety disorders. J Neuroimaging. 2006;16:1-10.
47. Bremner JD, Elzinga B, Schmali C, Vermetten E. Structural and functional plasticity of the human brain in posttraumatic stress disorder. Prog Brain Res. 2008;167:135-156.
48. Robinson BL, Shergill SS. Imaging in posttraumatic stress disorder. Curr Opin Psychiatry. 2011;24:29-33.
49. Gilbertson MW, Benton ME, Cisweski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci. 2002;5:1242-1247.
50. Felmingham K, Williams LM, Whitford TJ, et al. Duration of posttraumatic stress disorder predicts hippocampal grey matter loss. Neuroreport. 2009;20:1402-1406.
51. Jang JH, Kim JH, Jung WH, et al. Functional connectivity in fronto-subcortical circuitry during the resting state in obsessive-compulsive disorder. Neurosci Lett. 2010;474:158-162.
52. Kang DH, Kwon JS, Kim JJ, et al. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatr Scand. 2003;107:291-297.
53. Breiter HC, Rauch SL, Kwong KK, et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53:595-606.
54. Schienle A, Schafer A, Stark R, Walter B, Voit D. Neural responses of OCD patients towards disorder-relevant, generally disgust-inducing and fear-inducing pictures. Int J Psychophysiol. 2005;57:69-77.
55. Simon D, Kaufmann C, Mushc K, Kischke E, Rathmann N. Fronto-striato-limbic hyperactivation in obsessive-compulsive disorder during individually tailored symptom provocation. Psychophysiology, 2010;47:728-738.
56. Kwon JS, Jang JH, Choi JS, Kang DH. Neuroimaging in obsessive-compulsive disorder. Expert Rev Neurother. 2008;9:255-269.
57. van den Heuvel OA, Veitman DJ, Groenewegen HJ, et al. Amygdala activity in obsessive-compulsive disorder with contamination fear: a study with oxygen-15 water positron emission tomography. Psychiatry Res. 2004;123:225-237.
58. Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr Clin North Am. 2010;33:557-577.
59. Goossens L, Suaert S, Peeters R, Griez EJ, Schruers KR. Amygdala hyperfunction in phobic fear normalizes after exposure. Biol Psychiatry. 2007;62:1119-1125.
60. Nakatani E, Nakgawa A, Ohara Y, et al. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Res. 2003;124:113-120.
61. Saxena S, Gorbis E, O’Neill J, et al. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry. 2009;14:197-205.
62. Dickie EW, Brunet A, Akerib V, Armony JL. Neural correlates of recovery from post-traumatic stress disorder: a longitudinal fMRI investigation of memory encoding. *Neuropsychologia*. 2011;49:1771-1778.
63. Dickie EW, Brunet A, Akerib V, Armony JL. An fMRI investigation of memory encoding in PTSD: influence of symptom severity. *Neuropsychologia*. 2008;46:1522-1531.
64. Grillon C. D-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms. *Biol Psychiatry*. 2009;66:636-641.
65. Aupperle RL, Hale LR, Chambers RJ, et al. An fMRI study examining effects of acute D-cycloserine during symptom provocation in spider phobia. *CNS Spectr*. 2009;14:556-571.
66. Goldin PR, Gross JJ. Effects of mindfulness-based stress reduction (MBSR) on emotion regulation in social anxiety disorder. *Emotion*. 2010;10:83-91.
67. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. *J Clin Psychiatry*. 2010;71:839-854.
68. Del-Ben CM, Deakin JF, McKenzie S, et al. The effect of citalopram pre-treatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. *Neuropsychopharmacology*. 2005;30:1724-1734.
69. Hoehn-Saric R, Schlund MW, Wong SH. Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. *Psychiatry Res*. 2004;131:11-21.
70. Aupperle RL, Ravindran L, Tankersley D, et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. *Neuropsychopharmacology*. 2011;36:1466-1477.
71. Carter CS, Grippio AJ, Pournajafi-Nazarloo H, Ruscio MG, Porges SW. Oxytocin, vasopressin and sociality. *Prog Brain Res*. 2008;170:331-336.
72. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. *Science*. 2008;322:900-904.
73. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. *Neuropsychopharmacology*. 2010;35:2403-2413.
74. McClure EB, Adler A, Monk CS, et al. fMRI predictors of treatment outcome in pediatric anxiety disorders. *Psychopharmacology (Berl)*. 2007;191:97-105.
75. Bryant RA, Felmingham K, Whitford TJ, et al. Rostral anterior cingulate volume predicts treatment response to cognitive-behavioural therapy for posttraumatic stress disorder. *J Psychiatry Neurosci*. 2008;33:142-146.